NTLA
Price
$12.21
Change
+$0.13 (+1.08%)
Updated
Dec 20, 04:59 PM (EDT)
61 days until earnings call
VRDN
Price
$19.04
Change
+$0.31 (+1.66%)
Updated
Dec 20, 04:59 PM (EDT)
67 days until earnings call
Ad is loading...

NTLA vs VRDN

Header iconNTLA vs VRDN Comparison
Open Charts NTLA vs VRDNBanner chart's image
Intellia Therapeutics
Price$12.21
Change+$0.13 (+1.08%)
Volume$70.18K
CapitalizationN/A
Viridian Therapeutics
Price$19.04
Change+$0.31 (+1.66%)
Volume$44.99K
CapitalizationN/A
NTLA vs VRDN Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. VRDN commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and VRDN is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (NTLA: $12.21 vs. VRDN: $19.04)
Brand notoriety: NTLA and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 129% vs. VRDN: 365%
Market capitalization -- NTLA: $1.24B vs. VRDN: $1.51B
NTLA [@Biotechnology] is valued at $1.24B. VRDN’s [@Biotechnology] market capitalization is $1.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • VRDN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both NTLA and VRDN are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а -5.35% price change this week, while VRDN (@Biotechnology) price change was +6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

VRDN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.51B) has a higher market cap than NTLA($1.24B). VRDN YTD gains are higher at: -12.580 vs. NTLA (-59.954). VRDN has higher annual earnings (EBITDA): -253.41M vs. NTLA (-527.52M). VRDN has more cash in the bank: 753M vs. NTLA (658M). VRDN has less debt than NTLA: VRDN (21.1M) vs NTLA (102M). NTLA has higher revenues than VRDN: NTLA (43.1M) vs VRDN (302K).
NTLAVRDNNTLA / VRDN
Capitalization1.24B1.51B82%
EBITDA-527.52M-253.41M208%
Gain YTD-59.954-12.580477%
P/E RatioN/AN/A-
Revenue43.1M302K14,272%
Total Cash658M753M87%
Total Debt102M21.1M483%
FUNDAMENTALS RATINGS
NTLA vs VRDN: Fundamental Ratings
NTLA
VRDN
OUTLOOK RATING
1..100
6865
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9254
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for VRDN (92). This means that NTLA’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that VRDN’s stock grew somewhat faster than NTLA’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as VRDN (98). This means that NTLA’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that VRDN’s stock grew somewhat faster than NTLA’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that VRDN’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAVRDN
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 26 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACIWX12.820.21
+1.67%
American Century Global Real Estate G
LADPX21.070.29
+1.40%
Lord Abbett Developing Growth P
OIOIX16.660.08
+0.48%
AXS Income Opportunities I
MRSHX22.12N/A
N/A
MFS Research International R3
MUXRX25.27N/A
N/A
Victory S&P 500 Index R

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+1.08%
VCYT - NTLA
69%
Closely correlated
+4.66%
EDIT - NTLA
68%
Closely correlated
-2.24%
BEAM - NTLA
66%
Loosely correlated
+8.16%
CRSP - NTLA
62%
Loosely correlated
+0.83%
PRME - NTLA
59%
Loosely correlated
+4.66%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with ALLO. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+1.66%
ALLO - VRDN
52%
Loosely correlated
+1.63%
FATE - VRDN
50%
Loosely correlated
+1.81%
CRBU - VRDN
46%
Loosely correlated
-0.83%
AURA - VRDN
46%
Loosely correlated
+1.23%
ABCL - VRDN
45%
Loosely correlated
+4.80%
More